Review Series 10.1172/JCI142243
Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Simeon I. Taylor, University of Maryland School of Medicine, HSF-III, Room 4182, 655 West Baltimore Street, Baltimore, Maryland 21201, USA. Phone: 410.706.6439; Email: staylor2@som.umaryland.edu.
Find articles by
Taylor, S.
in:
JCI
|
PubMed
|
Google Scholar
|
Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Simeon I. Taylor, University of Maryland School of Medicine, HSF-III, Room 4182, 655 West Baltimore Street, Baltimore, Maryland 21201, USA. Phone: 410.706.6439; Email: staylor2@som.umaryland.edu.
Find articles by Yazdi, Z. in: JCI | PubMed | Google Scholar
Division of Endocrinology, Diabetes, and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Address correspondence to: Simeon I. Taylor, University of Maryland School of Medicine, HSF-III, Room 4182, 655 West Baltimore Street, Baltimore, Maryland 21201, USA. Phone: 410.706.6439; Email: staylor2@som.umaryland.edu.
Find articles by
Beitelshees, A.
in:
JCI
|
PubMed
|
Google Scholar
|
Published January 19, 2021 - More info
Diabetes mellitus is a major public health problem, affecting about 10% of the population. Pharmacotherapy aims to protect against microvascular complications, including blindness, end-stage kidney disease, and amputations. Landmark clinical trials have demonstrated that intensive glycemic control slows progression of microvascular complications (retinopathy, nephropathy, and neuropathy). Long-term follow-up has demonstrated that intensive glycemic control also decreases risk of macrovascular disease, albeit rigorous evidence of macrovascular benefit did not emerge for over a decade. The US FDA’s recent requirement for dedicated cardiovascular outcome trials ushered in a golden age for understanding the clinical profiles of new type 2 diabetes drugs. Some clinical trials with sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists reported data demonstrating cardiovascular benefit (decreased risk of major adverse cardiovascular events and hospitalization for heart failure) and slower progression of diabetic kidney disease. This Review discusses current guidelines for use of the 12 classes of drugs approved to promote glycemic control in patients with type 2 diabetes. The Review also anticipates future developments with potential to improve the standard of care: availability of generic dipeptidylpeptidase-4 (DPP4) inhibitors and SGLT2 inhibitors; precision medicine to identify the best drugs for individual patients; and new therapies to protect against chronic complications of diabetes.
A subscription is required for you to read this article in full. If you are a subscriber, you may sign in to continue reading.
Click here to sign into your account.
Please select one of the subscription options, which includes a low-cost option just for this article.
If you are at an institution or library and believe you should have access, please check with your librarian or administrator (more information).
Please try these troubleshooting tips.